Cancentus is a cancer treatment company that provides AI-based disease discovery solutions.
Cancentus has raised $636K in total funding. The most recent round was Convertible Note. The last funding was announced in April 2026.
Cancentus's investors include BaseLaunch.
Cancentus is headquartered in Allschwil, Switzerland.
Cancentus is a cancer treatment company that provides AI-based disease discovery solutions.
Cancentus is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cancentus — Funding & Investors." VCBacked, April 26, 2026, https://www.vcbacked.co/company/cancentus. Accessed November 12, 2026.
VCBacked. (2026). Cancentus — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/cancentus
{{cite web |title=Cancentus — Funding & Investors |url=https://www.vcbacked.co/company/cancentus |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Cancentus? Request a listing update